Associated tags: Erosion (morphology), Blepharitis, NovaBay Pharmaceuticals, Health, NYSE, Pharmaceutical, Optical, Biotechnology, Cosmetics, NBY, Retail, Pharmaceutical industry, Women, Consumer
Locations: UNITED STATES, NORTH AMERICA, CALIFORNIA, NO
Retrieved on:
Tuesday, November 29, 2022
Apps,
Applications,
Technology,
Marketing,
Communications,
Social Media,
Pharmaceutical,
Health,
Cosmetics,
Optical,
Retail,
NovaBay Pharmaceuticals,
Tmall,
Blepharitis,
Double,
Reverse stock split,
B2B,
Internet,
NYSE,
Black Friday,
Motherboard,
HK,
Online shopping,
Marketing,
TikTok,
Amazon We recently ran a successful campaign in China during the 12 days of Double 11, so named because it ends on November 11th.
Key Points:
- We recently ran a successful campaign in China during the 12 days of Double 11, so named because it ends on November 11th.
- Earlier this year, we engaged Doumai, a leading e-commerce solution provider, to refresh our DERMAdoctor e-commerce store on TMall, the Chinese counterpart to Amazon in China.
- Im pleased to say that our online store has gained 15,000 followers, with more than 30,000 consumers so far placing DERMAdoctor product orders through Tmall.
- NovaBay Pharmaceuticals, Inc. is a pharmaceutical company that develops and sells scientifically created and clinically proven eyecare and skincare products.
Retrieved on:
Thursday, November 17, 2022
Women,
Biotechnology,
Family,
Health,
Cosmetics,
Consumer,
Pharmaceutical,
Retail,
Optical,
Medical News Schering,
Skin,
Linoleic acid,
Medical News Today,
Form,
NovaBay Pharmaceuticals,
Itchy,
NYSE,
Security (finance),
Asthma,
Red,
Milgram & Company Ltd.,
QVC,
Atopic dermatitis,
Register,
MD,
Ceramide,
Dermatitis,
Blepharitis,
Publication,
Cosmetics,
Amazon (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that Chief Product Officer Audrey Kunin, MD will return for her fourth appearance this year on the QVC network.
Key Points:
- (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that Chief Product Officer Audrey Kunin, MD will return for her fourth appearance this year on the QVC network.
- I am excited to share our moisture-rich, problem-solving Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm on QVC just in time for holiday giving, said Dr. Kunin.
- Dry indoor air during the winter months can exacerbate parched, eczema-prone skin, leading to itching, redness and discomfort.
- Dr. Kunin is a board-certified dermatologist, author, clinician, educator, television personality and recognized trailblazer in the skincare industry.
Retrieved on:
Monday, November 14, 2022
Pharmaceutical,
Health,
Optical,
Effective date,
Commission,
NYSE American,
Reverse stock split,
CUSIP,
NovaBay Pharmaceuticals,
Proxy,
NYSE,
Treasury,
Ashbury Railway Carriage and Iron Company Ltd,
Computershare,
Bangladesh Securities and Exchange Commission,
Blepharitis,
Security (finance),
Amazon The reverse stock split will not reduce the number of authorized shares of common stock or authorized shares of preferred stock or change the par values of the Companys common stock (which will remain at $0.01 per share) or preferred stock (which will also remain at $0.01 per share).
Key Points:
- The reverse stock split will not reduce the number of authorized shares of common stock or authorized shares of preferred stock or change the par values of the Companys common stock (which will remain at $0.01 per share) or preferred stock (which will also remain at $0.01 per share).
- Except for adjustments resulting from the treatment of fractional shares, each stockholder will hold the same percentage of our outstanding common stock immediately following the reverse stock split as such stockholder held immediately prior to the reverse stock split.
- Because the reverse stock split will not reduce the number of authorized shares of common stock, the effect of the reverse stock split will be to increase the number of common shares available for issuance relative to the number of common shares issued and outstanding.
- The reverse stock split will not alter the par value of the Companys common stock or modify any voting rights or other terms of the common stock.
Retrieved on:
Monday, November 14, 2022
Biotechnology,
Pharmaceutical,
Optical,
Health,
R,
Marketing,
PIN,
NYSE American,
Series,
Traction,
NovaBay Pharmaceuticals,
Warrant,
G&A,
NYSE,
Lamson Engineering Company Ltd,
Acquisition,
Security (finance),
Financial result,
Shareholder,
Growth,
Research,
Blepharitis,
Retail,
Pharmaceutical industry,
Video game,
Risk management,
Amazon (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2022 and provides a business update.
Key Points:
- (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2022 and provides a business update.
- Financial results for the first nine months of 2022 include DERMAdoctor, which NovaBay acquired on November 5, 2021.
- Sales and marketing expenses were $1.8 million for the third quarter of 2022, compared with $2.1 million for the third quarter of 2021.
- Operating expenses for the third quarter of 2022 were $2.8 million, compared with $3.8 million for the third quarter of 2021.
Retrieved on:
Wednesday, November 9, 2022
Biotechnology,
Pharmaceutical,
Optical,
Health,
PIN,
NovaBay Pharmaceuticals,
NYSE,
Webcast,
Solution,
Company,
Blepharitis,
Pharmaceutical industry,
Online shopping,
Amazon NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and nine months ended September 30, 2022 after market close on Monday, November 14, 2022 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.
Key Points:
- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and nine months ended September 30, 2022 after market close on Monday, November 14, 2022 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.
- Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator.
- Those who choose not to pre-register can access the live conference call by dialing the following and requesting the NovaBay Pharmaceuticals call:
866-777-2509 from within the U.S.
412-317-5413 from outside the U.S.
- NovaBay Pharmaceuticals, Inc. develops and sells problem-solving, accessible solutions for improved well-being in the eyecare, skincare, and wound care markets.
Retrieved on:
Wednesday, October 26, 2022
Cosmetics,
Retail,
Health,
Consumer,
Women,
Other Health,
Pharmaceutical,
Sunlight,
NovaBay Pharmaceuticals,
Securities Act of 1933,
SEC,
Woman,
NYSE,
PH,
Collagen,
Target Corporation,
Antioxidant,
Multimedia,
Inflammation,
Reverse stock split,
Serum,
MD,
Zinc,
Securities Exchange Act of 1934,
Skin,
QVC,
Costco,
Peptide,
Acne,
Amazon (company),
Cosmetics NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces the newest addition to the DERMAdoctor Picture Porefect collection: 15% Niacinamide Pore Minimizing Serum .
Key Points:
- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces the newest addition to the DERMAdoctor Picture Porefect collection: 15% Niacinamide Pore Minimizing Serum .
- View the full release here: https://www.businesswire.com/news/home/20221026005007/en/
DERMAdoctor Picture Porefect 15% Niacinamide Pore Minimizing Serum (Photo: Business Wire)
The appearance of enlarged pores is a concern of many women who strive to achieve their most beautiful complexion, said NovaBay Chief Product Officer Audrey Kunin, MD, a board-certified dermatologist.
- Our new supercharged 15% Niacinamide Pore Minimizing Serum helps neutralize the effects of environmental stressors such as sunlight, pollution and toxins, leaving skin looking and feeling radiant.
- NovaBay Pharmaceuticals, Inc. is a pharmaceutical company that develops and sells scientifically created and clinically proven eyecare and skincare products.
Retrieved on:
Wednesday, October 19, 2022
Medical Supplies,
Clinical Trials,
Other Health,
Biotechnology,
General Health,
Pharmaceutical,
Health,
Cosmetics,
Optical,
Retail,
NYSE,
NovaBay Pharmaceuticals,
Online shopping,
Cosmetics (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces that management will present a company overview at the LD Micro Main Event XV on Wednesday, October 26 at 8:00 a.m. Pacific time (11:00 a.m. Eastern time).
Key Points:
- (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces that management will present a company overview at the LD Micro Main Event XV on Wednesday, October 26 at 8:00 a.m. Pacific time (11:00 a.m. Eastern time).
- The conference is being held at the Luxe Sunset Boulevard Hotel in Los Angeles.
- A webcast of the live and archived presentation will be available on the Events page of the company website.
- NovaBay Pharmaceuticals, Inc. is a pharmaceutical company that develops and sells scientifically created and clinically proven eyecare and skincare products.
Retrieved on:
Tuesday, October 18, 2022
Biotechnology,
Health,
Cosmetics,
Retail,
Pharmaceutical,
NovaBay Pharmaceuticals,
Drug Quality and Security Act,
SEC,
NYSE,
PH,
Target Corporation,
Securities Act of 1933,
Reverse stock split,
MD,
Securities Exchange Act of 1934,
QVC,
Costco,
Amazon (company),
Cosmetics,
Kakadu (NYSE American: NBY) announces significant orders for DERMAdoctor Kakadu C 20% Vitamin C Serum with Ferulic Acid & Vitamin E.
Key Points:
- (NYSE American: NBY) announces significant orders for DERMAdoctor Kakadu C 20% Vitamin C Serum with Ferulic Acid & Vitamin E.
We are excited to share that one of our best-selling products, DERMAdoctor Kakadu C serum, continues its popularity this year with several large orders just in time for the holiday season, said Justin Hall, NovaBay CEO.
- Best-selling, antioxidant-rich Kakadu C serum helps to visibly brighten and even skin tone while also improving the appearance of skin elasticity, fine lines and wrinkles.
- This clinical-strength serum features 20% stabilized vitamin C and is formulated with superfruit Kakadu plum, which is wild-harvested in the remote Kimberley region of Australia.
- The Kakadu C collection was formulated by NovaBay Chief Product Officer, Audrey Kunin, MD, a board-certified dermatologist.
Other Health,
General Health,
Other Retail,
Online Retail,
Pharmaceutical,
Optical,
Specialty,
Consumer,
Cosmetics,
Retail,
Biotechnology,
Women,
Health,
NovaBay Pharmaceuticals,
Securities Act of 1933,
SEC,
NYSE,
Securities Exchange Act of 1934,
Reverse stock split,
History,
Black Friday,
Moist,
Amazon (company),
KP duty,
Online shopping,
Cosmetics,
MD,
Amazon (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces that select Avenova brand products and all DERMAdoctor brand products will be featured with discounts to Amazon Prime members during the Amazon Prime Early Access Sale being held October 11-12, 2022.
Key Points:
- (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces that select Avenova brand products and all DERMAdoctor brand products will be featured with discounts to Amazon Prime members during the Amazon Prime Early Access Sale being held October 11-12, 2022.
- The Early Access Sale also provides Black Friday-level deals for early holiday shoppers.
- DERMAdoctor collections included in the Amazon Prime Early Access Sale include Aint Misbehavin, Calm Cool + Corrected, Kakadu C, KP Duty, Lucky Bamboo, Specialists, Urban Veil and Wrinkle Revenge.
- NovaBay Pharmaceuticals, Inc. is a pharmaceutical company that develops and sells scientifically created and clinically proven eyecare and skincare products.
Family,
Health,
Consumer,
Women,
Other Health,
Optical,
Biotechnology,
U.S. Securities and Exchange Commission,
Time,
NovaBay Pharmaceuticals,
Securities Act of 1933,
SEC,
Growth,
Attention,
LLC,
NYSE,
THE,
Security (finance),
NYSE American,
Corporation,
Reverse stock split,
Company,
Powell Street station,
Internet,
Â,
Securities Exchange Act of 1934,
Special,
Suite,
Compliance,
Online shopping,
Shareholder (NYSE American: NBY) announces that on October 3, 2022 it received a notice from the NYSE American LLC that the Companys common stock has been selling for a low price per share for a substantial period of time.
Key Points:
- (NYSE American: NBY) announces that on October 3, 2022 it received a notice from the NYSE American LLC that the Companys common stock has been selling for a low price per share for a substantial period of time.
- The notice from the NYSE American has no immediate effect on the listing or trading of the Companys common stock, and the common stock will continue to trade on the NYSE American.
- In addition, the reverse stock split may improve the marketability and liquidity of its common stock, and appeal to a broader range of investors.
- NovaBay Pharmaceuticals, Inc. is a pharmaceutical company that develops and sells scientifically created and clinically proven eyecare and skincare products.
